Jiao Fengjuan, Zhou Lincong, Wu Zaixin
School of Mental Health, Jining Medical University, No. 45, Jianshe South Road, Jining City, Shandong Province, 272067, P. R. China.
Shandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jining, Shandong, 272067, P. R. China.
Neurol Sci. 2025 Feb;46(2):561-578. doi: 10.1007/s10072-024-07878-x. Epub 2024 Nov 15.
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by motor symptoms and non-motor symptoms. It has been found that intestinal issues usually precede motor symptoms. Microorganisms in the gastrointestinal tract can affect central nervous system through the microbiota-gut-brain axis. Accumulating evidence has shown that disturbances in the microbiota-gut-brain axis are linked with PD. Thus, this pathway appears to be a promising therapeutic target for treatment of PD.
In this review, we mainly described gut dysbiosis in PD and their underlying mechanisms for mediating neuroinflammation and peripheral immune response in PD pathology and futher discussed the potential small-molecule compounds and genic therapeutic strategies targeting the microbiota-gut-brain axis and their applications in PD.
Studies have found that some small molecule compounds and alterations of inflammation-related genes can improve the motor and non-motor symptoms of PD by improving the microbiota-gut-brain axis, which may provide potentially beneficial drugs and molecular targets for the therapies of PD.
帕金森病（PD）是一种常见的神经退行性疾病，其特征为运动症状和非运动症状。已发现肠道问题通常先于运动症状出现。胃肠道中的微生物可通过微生物群-肠-脑轴影响中枢神经系统。越来越多的证据表明，微生物群-肠-脑轴的紊乱与帕金森病有关。因此，该途径似乎是治疗帕金森病的一个有前景的治疗靶点。
在本综述中，我们主要描述了帕金森病中的肠道菌群失调及其在帕金森病病理中介导神经炎症和外周免疫反应的潜在机制，并进一步讨论了针对微生物群-肠-脑轴的潜在小分子化合物和基因治疗策略及其在帕金森病中的应用。
研究发现，一些小分子化合物和炎症相关基因的改变可通过改善微生物群-肠-脑轴来改善帕金森病的运动和非运动症状，这可能为帕金森病的治疗提供潜在的有益药物和分子靶点。
